Saldarriaga Rivera Lina María, Fernández Ávila Daniel, Bautista Molano Wilson, Jaramillo Arroyave Daniel, Bautista Ramírez Alain Jasaf, Díaz Maldonado Adriana, Hernán Izquierdo Jorge, Jáuregui Edwin, Latorre Muñoz María Constanza, Restrepo Juan Pablo, Segura Charry Juan Sebastián
Departamento de Medicina Interna, Unidad de Reumatología, Facultad de Medicina, Universidad Tecnológica de Pereira. Hospital Universitario San Jorge, Clínica Los Rosales, Pereira, Colombia.
Departamento de Medicina Interna, Unidad de Reumatología, Facultad de Medicina, Pontificia Universidad Javeriana. Hospital Universitario San Ignacio, Bogotá, Colombia.
Rev Colomb Reumatol. 2020 Jul-Sep;27(3):230-241. doi: 10.1016/j.rcreu.2020.05.007. Epub 2020 Jun 12.
To produce recommendations for patients with rheumatological diseases receiving immunomodulatory and immunosuppressive therapies (conventional drugs, biologicals, and small molecules) during the COVID-19 pandemic.
The recommendations were determined using the Delphi method as an agreement tool. A panel of experts was formed, with academic backgrounds and research experience in rheumatology. A literature search was conducted and 42 questions were generated. The level of agreement was made with 80% of approval by the participants.
A group of eleven rheumatologists from 7 cities in the country participated. The response rate was 100% for the three consultation rounds. In the first round, agreement was reached on 35 questions, on 37 in the second round, and on 42 questions in the third round.
The recommendation for the majority of the pharmacological treatments used in rheumatology is to continue with immunomodulatory or immunosuppressive therapies in patients who do not have the infection, and to suspend it in patients with a diagnosis of SARS-CoV-2/COVID-19.
为在2019冠状病毒病大流行期间接受免疫调节和免疫抑制治疗（传统药物、生物制剂和小分子药物）的风湿病患者制定建议。
使用德尔菲法作为达成共识的工具来确定这些建议。组建了一个由具有风湿病学学术背景和研究经验的专家组成的小组。进行了文献检索并提出了42个问题。以参与者80%的认可率达成共识水平。
来自该国7个城市的11名风湿病学家参与其中。三轮咨询的回复率均为100%。第一轮就35个问题达成了共识，第二轮为37个，第三轮为42个。
对于风湿病中使用的大多数药物治疗的建议是，未感染的患者继续进行免疫调节或免疫抑制治疗，而诊断为严重急性呼吸综合征冠状病毒2/2019冠状病毒病的患者则暂停治疗。
